Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.
Lead Product(s): ENA-001
Therapeutic Area: Sleep Product Name: ENA-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Eagle Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.
Lead Product(s): ENA-001
Therapeutic Area: Sleep Product Name: ENA-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
In partnership with BARDA, ENA-001 is being developed in an intramuscular (“IM”) formulation for potential use in patients experiencing community drug overdose and as a potential medical countermeasure for mass casualty events.
Lead Product(s): ENA-001
Therapeutic Area: Psychiatry/Psychology Product Name: ENA-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $56.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2022
Details:
Rare Pediatric Disease Designation received for ENA-001, a unique agnostic respiratory stimulant has the potential to significantly improve the standard of care for neonates experiencing life-threatening and debilitating respiratory conditions.
Lead Product(s): ENA-001
Therapeutic Area: Sleep Product Name: ENA-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021